Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 11Neoplasms 5Parasomnias 4Depression 3Weight Loss 2Tuberous Sclerosis 2Smith-Magenis Syndrome 2Sleep Wake Disorders 2Polycystic Ovary Syndrome 2Pain 2Lung Neoplasms 2Fatigue 2Cachexia 2Autism Spectrum Disorder 2Anxiety Disorders 2Angelman Syndrome 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sleep Disorders, Circadian Rhythm 1Relapsed Malignant Solid Tumor 1Radiodermatitis 1Radiation Injuries 1Quality of Life 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Melanoma 1Leukoplakia, Oral 1Keratosis, Actinic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × Melatonin × Clear all
NCT02190838 2019-11-25

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

N.N. Petrov National Medical Research Center of Oncology

Phase 2 Terminated
57 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡